Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein–protein interaction through structure-based drug design
Daniel J. Parks(Johnson & Johnson (United States)), Tianbao Lu(Johnson & Johnson (United States)), Diane Maguire(Johnson & Johnson (United States)), Maxwell D. Cummings(Johnson & Johnson (United States)), Louis V. LaFrance(Johnson & Johnson (United States)), Pierre Raboisson(Johnson & Johnson (United States)), Anna C. Maroney(AbbVie (United States)), Raul R. Calvo(Johnson & Johnson (United States)), Bruce Grasberger(Johnson & Johnson (United States)), Juan Marugán(National Institutes of Health), Theodore E. Carver(Johnson & Johnson (United States)), Karen L. Milkiewicz(Johnson & Johnson (United States)), Carsten J. Schubert(Johnson & Johnson (United States)), Carol F. Franks(Johnson & Johnson (United States)), Jennifer Lattanze(Johnson & Johnson (United States)), Shuyuan Zhao(Johnson & Johnson (United States)), Holly K. Koblish(Wilmington University)
Cited by 76
Related Papers
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
|Journal of Medicinal Chemistry|2005|430
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
|ACS Medicinal Chemistry Letters|2012|377
Motoneuron Apoptosis Is Blocked by CEP-1347 (KT 7515), a Novel Inhibitor of the JNK Signaling Pathway
|Journal of Neuroscience|1998|293